EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Advances To Second Cohort In Pharmacokinetics Study Of AD04 For The Treatment Of Alcohol Use Disorder
Portfolio Pulse from Benzinga Newsdesk
Adial Pharmaceuticals has advanced to the second cohort in its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. This progress marks a significant step in the development of the drug.
July 23, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adial Pharmaceuticals has made significant progress by advancing to the second cohort in its pharmacokinetics study of AD04 for Alcohol Use Disorder treatment.
Advancing to the second cohort in a pharmacokinetics study is a positive development, indicating progress in the drug's development. This can boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100